Catalog No.	C031P
Product Name	Nimotuzumab Biosimilar, Anti-human EGFR Antibody | C031P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Source/Host	The anti-human EGFR monoclonal antibody nimotuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The research grade nimotuzumab biosimilar specifically binds to the human epidermal growth factor receptor (EGFR).
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 ug of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade nimotuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

C031P: Nimotuzumab Biosimilar (Research Grade), Anti-human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.

Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.

It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.

Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Syd Labs also provides the following anti-EGFR antibody biosimilar proteins:
Cetuximab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Matuzumab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Panitumumab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Zalutumumab Biosimilar, research grade, anti-human EGFR monoclonal antibody

Nimotuzumab Biosimilar from: Nimotuzumab Biosimilar, Anti-human EGFR Antibody: C031P Syd Labs

No more offers for this product!